Healthcare & Life Science

KO client Kiora Pharmaceuticals, a clinical-stage biotechnology company focused on developing innovative therapies for ophthalmic diseases, recently announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD), one of South Korea’s leading pharmaceutical companies. KIO-301…

KO client Kailera Therapeutics, a clinical-stage biotechnology company focused on elevating the next era of obesity care, recently announced positive topline data from two Phase 3 clinical trials for people living with obesity or type 2 diabetes. KO partner Brad Schoenfeld and attorney John Shearer represented Kailera in getting the…

KO client Elpida Therapeutics, a nonprofit biotechnology company dedicated to developing treatments for ultra-rare pediatric neurological diseases, recently announced that it has entered into an assignment and license agreement with Ionis Pharmaceuticals for ION283, an investigational antisense oligonucleotide (ASO) therapy for Lafora disease. The agreement is expected to advance the…

KO client InDevR, a provider of advanced multiplexed solutions for vaccine testing and quality control, was recently acquired by SSI Diagnostica Group (SSID Group), a global company specializing in testing solutions for infectious diseases. InDevR will advance SSID Group’s offering by adding recognized expertise in influenza and mRNA vaccine QC…

KO client Finding Hope for Frizzle (FRRS1L), a parent-led nonprofit organization working to develop a lifesaving treatment for FRRS1L patients, and Apertura Gene Therapy recently announced a license agreement to develop a gene therapy using Apertura’s TfR1 CapX technology. “Although FRRS1L is a horrible and devastating disease robbing children of…

Looking ahead, there is a sense of optimism for the 2026 M&A landscape. The surge in deal value and the reopening of the IPO window in late 2025 have signaled a much-needed return of market liquidity. We are seeing a convergence of expectations: recent down-round IPOs suggest that sellers and…

KO client VitriVax, a vaccine formulation technology company, recently announced that it has completed a $17.25 million Series B financing. The round was co-led by Adjuvant Capital and RA Capital Management and will advance VitriVax’s ALTA® thermostable vaccine platform and support the next phase of its clinical and regulatory journey.…

KO client Pluto Bio, the leading AI-powered platform for computational biology, recently raised $3.6 million in new funding to accelerate growth and scale adoption of its enterprise-grade platform among global pharma companies. According to the announcement, the round includes participation from new investor Kickstart, alongside existing investor Silverton Partners and…